Esophageal Adenocarcinoma

News alerts, weekly reports and conference planners

Related cancers:

‹

Esophageal Cancer (155)

Esophageal Squamous Cell Carcinoma (69)

Esophageal Cancer (155)

Esophageal Squamous Cell Carcinoma (69)

›

HER-2 negative + PD-L1 expression	Esophageal Adenocarcinoma	HER-2 negative + PD-L1 expression	Esophageal Adenocarcinoma	nivolumab Sensitive: A1 - Approval NICE - 6 days (New A2) nivolumab Sensitive : A1 NICE - 6d	nivolumab Sensitive: A1 - Approval NICE - 6 days nivolumab Sensitive : A1 NICE - 6 days - (New A2)
HER-2 positive	Esophageal Adenocarcinoma	HER-2 positive	Esophageal Adenocarcinoma	trastuzumab + pertuzumab Sensitive: C1 - Off-label J Clin Oncol - 2 weeks (New C3) trastuzumab + pertuzumab Sensitive : C1 J Clin Oncol - 2wk	trastuzumab + pertuzumab Sensitive: C1 - Off-label J Clin Oncol - 2 weeks trastuzumab + pertuzumab Sensitive : C1 J Clin Oncol - 2 weeks - (New C3)
No biomarker	Esophageal Adenocarcinoma	No biomarker	Esophageal Adenocarcinoma	nivolumab Sensitive: A1 - Approval nivolumab Sensitive : A1	nivolumab Sensitive: A1 - Approval nivolumab Sensitive : A1
No biomarker	Esophageal Adenocarcinoma	No biomarker	Esophageal Adenocarcinoma	ramucirumab Sensitive: A2 - Guideline ramucirumab Sensitive : A2	ramucirumab Sensitive: A2 - Guideline ramucirumab Sensitive : A2
HER-2 positive	Esophageal Adenocarcinoma	HER-2 positive	Esophageal Adenocarcinoma	trastuzumab Sensitive: A2 - Guideline trastuzumab Sensitive : A2	trastuzumab Sensitive: A2 - Guideline trastuzumab Sensitive : A2
HER-2 overexpression	Esophageal Adenocarcinoma	HER-2 overexpression	Esophageal Adenocarcinoma	trastuzumab Sensitive: A2 - Guideline trastuzumab Sensitive : A2	trastuzumab Sensitive: A2 - Guideline trastuzumab Sensitive : A2
PD-L1 expression	Esophageal Adenocarcinoma	PD-L1 expression	Esophageal Adenocarcinoma	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2
No biomarker	Esophageal Adenocarcinoma	No biomarker	Esophageal Adenocarcinoma	FP Sensitive: A2 - Guideline FP Sensitive : A2	FP Sensitive: A2 - Guideline FP Sensitive : A2
No biomarker	Esophageal Adenocarcinoma	No biomarker	Esophageal Adenocarcinoma	FLOT Sensitive: A2 - Guideline FLOT Sensitive : A2	FLOT Sensitive: A2 - Guideline FLOT Sensitive : A2
No biomarker	Esophageal Adenocarcinoma	No biomarker	Esophageal Adenocarcinoma	FOLFOX Sensitive: A2 - Guideline FOLFOX Sensitive : A2	FOLFOX Sensitive: A2 - Guideline FOLFOX Sensitive : A2
HER-2 overexpression	Esophageal Adenocarcinoma	HER-2 overexpression	Esophageal Adenocarcinoma	fam-trastuzumab deruxtecan-nxki Sensitive: A2 - Guideline fam-trastuzumab deruxtecan-nxki Sensitive : A2	fam-trastuzumab deruxtecan-nxki Sensitive: A2 - Guideline fam-trastuzumab deruxtecan-nxki Sensitive : A2
PD-L1 expression	Esophageal Adenocarcinoma	PD-L1 expression	Esophageal Adenocarcinoma	nivolumab Sensitive: B - Late Trials nivolumab Sensitive : B	nivolumab Sensitive: B - Late Trials nivolumab Sensitive : B
PD-L1 overexpression	Esophageal Adenocarcinoma	PD-L1 overexpression	Esophageal Adenocarcinoma	nivolumab Sensitive: B - Late Trials nivolumab Sensitive : B	nivolumab Sensitive: B - Late Trials nivolumab Sensitive : B
PD-L1 underexpression	Esophageal Adenocarcinoma	PD-L1 underexpression	Esophageal Adenocarcinoma	Immunotherapy Resistant: B - Late Trials Immunotherapy Resistant : B	Immunotherapy Resistant: B - Late Trials Immunotherapy Resistant : B
MSI-H/dMMR	Esophageal Adenocarcinoma	MSI-H/dMMR	Esophageal Adenocarcinoma	nivolumab + ipilimumab Sensitive: C1 - Off-label nivolumab + ipilimumab Sensitive : C1	nivolumab + ipilimumab Sensitive: C1 - Off-label nivolumab + ipilimumab Sensitive : C1
CLDN18.2 expression	Esophageal Adenocarcinoma	CLDN18.2 expression	Esophageal Adenocarcinoma	IMAB362 Sensitive: C2 – Inclusion Criteria IMAB362 Sensitive : C2	IMAB362 Sensitive: C2 – Inclusion Criteria IMAB362 Sensitive : C2
HER-2 amplification	Esophageal Adenocarcinoma	HER-2 amplification	Esophageal Adenocarcinoma	trastuzumab + avelumab Sensitive: C2 – Inclusion Criteria trastuzumab + avelumab Sensitive : C2	trastuzumab + avelumab Sensitive: C2 – Inclusion Criteria trastuzumab + avelumab Sensitive : C2
HER-2 positive	Esophageal Adenocarcinoma	HER-2 positive	Esophageal Adenocarcinoma	paclitaxel Resistant: C3 – Early Trials paclitaxel Resistant : C3	paclitaxel Resistant: C3 – Early Trials paclitaxel Resistant : C3
HER-2 positive	Esophageal Adenocarcinoma	HER-2 positive	Esophageal Adenocarcinoma	carboplatin Resistant: C3 – Early Trials carboplatin Resistant : C3	carboplatin Resistant: C3 – Early Trials carboplatin Resistant : C3
ARID1A mutation	Esophageal Adenocarcinoma	ARID1A mutation	Esophageal Adenocarcinoma	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3
DKK1 overexpression	Esophageal Adenocarcinoma	DKK1 overexpression	Esophageal Adenocarcinoma	pembrolizumab + DKN-01 Sensitive: C3 – Early Trials pembrolizumab + DKN-01 Sensitive : C3	pembrolizumab + DKN-01 Sensitive: C3 – Early Trials pembrolizumab + DKN-01 Sensitive : C3
DKK1 overexpression	Esophageal Adenocarcinoma	DKK1 overexpression	Esophageal Adenocarcinoma	DKN-01 Sensitive: C3 – Early Trials DKN-01 Sensitive : C3	DKN-01 Sensitive: C3 – Early Trials DKN-01 Sensitive : C3
GRB7 positive	Esophageal Adenocarcinoma	GRB7 positive	Esophageal Adenocarcinoma	trastuzumab + pertuzumab Sensitive: C3 – Early Trials trastuzumab + pertuzumab Sensitive : C3	trastuzumab + pertuzumab Sensitive: C3 – Early Trials trastuzumab + pertuzumab Sensitive : C3
HER-2 overexpression	Esophageal Adenocarcinoma	HER-2 overexpression	Esophageal Adenocarcinoma	trastuzumab + pertuzumab Sensitive: C3 – Early Trials trastuzumab + pertuzumab Sensitive : C3	trastuzumab + pertuzumab Sensitive: C3 – Early Trials trastuzumab + pertuzumab Sensitive : C3
ERCC1 negative	Esophageal Adenocarcinoma	ERCC1 negative	Esophageal Adenocarcinoma	SOX Sensitive: C3 – Early Trials SOX Sensitive : C3	SOX Sensitive: C3 – Early Trials SOX Sensitive : C3
HER-2 positive	Esophageal Adenocarcinoma	HER-2 positive	Esophageal Adenocarcinoma	nivolumab + trastuzumab Sensitive: C3 – Early Trials nivolumab + trastuzumab Sensitive : C3	nivolumab + trastuzumab Sensitive: C3 – Early Trials nivolumab + trastuzumab Sensitive : C3
PD-L1 overexpression	Esophageal Adenocarcinoma	PD-L1 overexpression	Esophageal Adenocarcinoma	durvalumab Sensitive: C3 – Early Trials durvalumab Sensitive : C3	durvalumab Sensitive: C3 – Early Trials durvalumab Sensitive : C3
MSI-H/dMMR + MLH1 deletion + PMS2 deletion	Esophageal Adenocarcinoma	MSI-H/dMMR + MLH1 deletion + PMS2 deletion	Esophageal Adenocarcinoma	pembrolizumab Sensitive: C4 – Case Studies pembrolizumab Sensitive : C4	pembrolizumab Sensitive: C4 – Case Studies pembrolizumab Sensitive : C4
TP53 mutation	Esophageal Adenocarcinoma	TP53 mutation	Esophageal Adenocarcinoma	APR-246 Sensitive: D – Preclinical APR-246 Sensitive : D	APR-246 Sensitive: D – Preclinical APR-246 Sensitive : D

Esophageal Adenocarcinoma

Associations(29)

Associations
(29)